Buy AOD-9604 in Canada: The 10 mg Vial and What the Research Shows

You can buy AOD-9604 in Canada from Vistara Labs as 5 mg and 10 mg lyophilised vials, shipped from within Canada by Canada Post Xpresspost. AOD-9604 is a 16-amino-acid peptide taken from the C-terminal end of human growth hormone: the hormone’s 177–191 sequence with a tyrosine added at the start. It was first studied at Monash University in Australia as the part of growth hormone that drives fat breakdown, and it went on to six randomised, placebo-controlled human trials between 2001 and 2006. This guide covers the vial, what the research found and how ordering works.

Findings

• Human safety, 2013: pooled data from six randomised, double-blind, placebo-controlled trials in 893 adults showed a safety and tolerability profile indistinguishable from placebo (Journal of Endocrinology and Metabolism).
• No IGF-1 rise: across those trials AOD-9604 had no effect on serum IGF-1 and no negative effect on glucose tolerance, and no antibodies against the peptide were detected.
• Weight, 12 weeks: participants receiving AOD-9604 lost an average of 2.6 kg against 0.8 kg on placebo (Clinical Pharmacology & Therapeutics, 2010).
• Fat metabolism, 2001: in preclinical obesity models, AOD-9604 reduced weight gain and increased fat oxidation and lipolysis without raising blood glucose, and it did not bind the growth hormone receptor (International Journal of Obesity).
• Cartilage, 2015: in a laboratory model of knee osteoarthritis, AOD-9604 injected into the joint enhanced cartilage regeneration, and more so when combined with hyaluronic acid (Annals of Clinical & Laboratory Science).

What is in the AOD-9604 vial?

Property	AOD-9604
Product	AOD-9604, 10 mg lyophilised vial
Length	16 amino acids
Origin	hGH residues 177–191 plus an N-terminal tyrosine
Molecular weight	About 1815 Da
Preparation	Reconstitute with bacteriostatic water
Other names	AOD9604, Tyr-hGH 177–191, often listed as HGH Fragment 176–191

The vial holds freeze-dried powder that is reconstituted with bacteriostatic water before laboratory use.

What is AOD-9604?

Growth hormone is a 191-amino-acid protein, and in the 1990s a research group at Monash University traced much of its effect on fat cells to the short stretch at its C-terminal end. A synthetic 177–191 peptide reproduced the hormone’s antilipogenic action, and the group then added a tyrosine to the start of the chain. Its developers describe that extra tyrosine as stabilising the peptide. The result, a hexadecapeptide (16 amino acids), was named AOD-9604, and the clinical programme was run by the Australian company Metabolic Pharmaceuticals.

The point of the design was selectivity. Full-length growth hormone raises IGF-1 and can reduce insulin sensitivity; AOD-9604 was built to keep the fat-metabolism signal without those effects. How it relates to the “HGH Fragment 176–191” name seen in many catalogues is set out in AOD-9604 vs HGH Fragment 176–191, and the full research story is in What is AOD-9604?

What has AOD-9604 research shown?

Human studies

• Six trials, 2001 to 2006. Six randomised, double-blind, placebo-controlled trials enrolled 893 adults, all but the first in people with obesity. AOD-9604 was given intravenously in the first two and by mouth, as capsules or tablets, in the other four.
• Safety, pooled 2013. The pooled analysis found a very good safety and tolerability profile indistinguishable from placebo, with no withdrawal or serious adverse event related to AOD-9604 in any of the trials.
• IGF-1 and glucose. AOD-9604 had no effect on serum IGF-1, and oral glucose tolerance tests showed no negative effect on carbohydrate metabolism, in contrast with full-length growth hormone.
• Weight, 12 weeks. In a 12-week randomised trial, participants receiving AOD-9604 lost an average of 2.6 kg, against 0.8 kg on placebo, a difference that a larger 24-week trial did not reproduce at statistical significance.

In 2014 AOD-9604 was designated Generally Recognised As Safe (GRAS) in the United States for use as an ingredient in foods and dietary supplements.

Preclinical studies

• Weight gain, 2000. In a preclinical obesity model, AOD-9604 given by mouth for 19 days cut weight gain by more than half against controls, raised lipolytic activity in fat tissue and, unlike intact growth hormone, had no adverse effect on insulin sensitivity.
• Fat oxidation, 2001. Over 14 days AOD-9604 reduced weight gain, increased fat oxidation and raised plasma glycerol, a marker of lipolysis. It did not cause high blood sugar, did not compete for the growth hormone receptor and did not trigger cell proliferation through it.
• Beta-3 receptors, 2001. AOD-9604 reduced body weight and body fat and restored expression of the beta-3 adrenergic receptor, the main lipolytic receptor on fat cells, to the levels seen in lean controls.
• Cartilage, 2015. In a laboratory osteoarthritis model, injections of AOD-9604 into the knee enhanced cartilage regeneration and shortened the period of impaired joint function, with the strongest effect when combined with hyaluronic acid.

Our weight loss and metabolism research notes cover the wider field.

Reconstituting the 10 mg vial

A 10 mg vial of AOD-9604 reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL, so 0.1 mL (10 units on a U-100 insulin syringe) holds 0.5 mg (500 mcg). The full mixing table for 1, 2, 3 and 5 mL is in how much bacteriostatic water for AOD-9604, the method is in how to reconstitute peptides, and the peptide calculator works out any other volume.

Which compounds are studied alongside AOD-9604?

AOD-9604 sits in the metabolism part of our catalogue. Tesamorelin is the closest relative by origin: it also comes from growth hormone research, but it works upstream, at the pituitary, and the two are compared in AOD-9604 vs Tesamorelin. Other metabolism compounds we stock include MOTS-c, 5-Amino-1MQ and cagrilintide. Our overview of peptides in weight loss research compares the main pathways.

How should AOD-9604 be stored?

The lyophilised powder is the stable form: keep unopened vials cold, dry and away from light until they are needed. Once reconstituted, keep the vial in the fridge at 2 to 8 °C, protected from light, and label it with the date and the concentration chosen. Our guide to storing research peptides covers the detail.

Where to buy AOD-9604 in Canada

• No customs step. Every order ships from within Canada.
• Same-day dispatch. Orders placed before 3 pm Pacific, Monday to Friday, leave the same business day by tracked Canada Post Xpresspost, with free Xpresspost on larger orders.
• Every province. We deliver across Canada, from British Columbia to the Atlantic provinces.
• Certificates. Certificates of analysis for our catalogue are published on our Lab Reports page.
• Payment. We accept Interac e-Transfer, all major credit cards and crypto (Bitcoin).
• The full catalogue. See buying peptides in Canada.

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone: the hormone’s C-terminal 177-191 sequence with an added tyrosine at the start. It was designed to keep growth hormone’s effect on fat metabolism without its effects on IGF-1 and blood sugar.

What did the human AOD-9604 trials show?

Pooled data from six randomised, double-blind, placebo-controlled trials in 893 adults showed a safety and tolerability profile indistinguishable from placebo, with no effect on serum IGF-1, no negative effect on glucose tolerance and no antibodies against the peptide.

What did AOD-9604 show for body weight?

In a 12-week randomised trial, participants receiving AOD-9604 lost an average of 2.6 kg, against 0.8 kg on placebo. In preclinical studies it reduced weight gain and increased fat oxidation and lipolysis.

How was AOD-9604 given in the human studies?

Intravenously in the first two trials and by mouth, as capsules or tablets, in the other four. The 5 mg and 10 mg vials are our lyophilised laboratory formats.

Where can I buy AOD-9604 in Canada?

Vistara Labs supplies AOD-9604 as 5 mg and 10 mg lyophilised vials, shipped from within Canada by Canada Post Xpresspost.

Sources: Wu Z, Ng FM. Biochem Mol Biol Int. 1993. PMID 8358331. Ng FM, et al. Horm Res. 2000. PMID 11146367. Heffernan MA, et al. Int J Obes Relat Metab Disord. 2001. PMID 11673763. Heffernan M, et al. Endocrinology. 2001. PMID 11713213. Valentino MA, et al. Clin Pharmacol Ther. 2010. PMID 20445536. Stier H, et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013. doi:10.4021/jem157w. AOD9604 awarded safe status in US. LabOnline. 2014. labonline.com.au. Cox HD, et al. Drug Test Anal. 2015. PMID 25208511. Kwon DR, Park GY. Ann Clin Lab Sci. 2015. PMID 26275694.

More on this: What Is AOD-9604? The Human and Laboratory Research.